MacroGenics (MGNX) Leerink Global Healthcare Conference 2026 summary

Strategic focus and leadership approach

• Emphasis on foundational value drivers and a focused, lean operational model to maximize ROI and prioritize key pipeline assets over the next few years.

• Early discontinuation of non-competitive programs, such as lorigerlimab in prostate cancer, to reallocate resources.

Pipeline and clinical program updates

• Lorigerlimab Phase 2 program is on partial clinical hold due to serious adverse events; working with FDA to resolve and aiming for a comprehensive clinical update by mid-2026.

• MGC026 (B7-H3 ADC) completed dose escalation, with expansion cohorts underway and a clinical update expected mid-2026.

• MGC028 (ADAM9 ADC) nearing completion of dose escalation, with a clinical update planned for the second half of 2026.

• MGC030, an ADC with an undisclosed target, is completing IND-enabling studies and targeting IND submission in Q3 2026.

Technology and competitive positioning

• ADC programs leverage Synaffix’s site-specific conjugation technology, offering uniform DAR, improved safety, and potent exatecan payloads.

• No ILD observed in MGC026 and MGC028, suggesting a safety advantage over competitors.

• B7-H3 and ADAM9 targets chosen for broad tumor expression and efficient internalization, with differentiated development strategies to avoid crowded indications.